
Opinion|Videos|December 16, 2024
Barriers to Implementing New CKD Treatments
Key Takeaways
- Identifying at-risk patients for CKD in Type 2 Diabetes involves assessing hypertension, family history, and blood glucose levels.
- Screening tests for CKD include eGFR and UACR, essential for early detection in diabetic patients.
Panelists discuss the common barriers to implementing new chronic kidney disease (CKD) treatments and guidelines in clinical practice, as well as the role of pharmaceutical partners in overcoming these challenges to enhance CKD treatment adoption.
Advertisement
- What are the common barriers to implementing new CKD treatments and guidelines in clinical practice?
- What role do pharmaceutical partners play in overcoming challenges in CKD treatment adoption?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
VIASKIN Peanut Patch Efficacy Holds in Kids With Atopic Comorbidities
2
Fezolinetant Shows No CNS Safety Signal in Pooled Analysis of 3100 Women, With Marla Shapiro, CM
3
CAPTAIN-T2D: Interim Results Display High Cortisol Prevalence in Difficult-to-Control T2D
4
Rethinking “Type 2”: Inside the 2026 AACE Diabetes Classification Algorithm
5
























































